Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|November 13, 2014
- NSCLC (Issue 5)
- Volume 5
- Issue 1
The Future of Squamous Cell Lung Cancer Treatment
Author(s)Peter Hammerman, MD, PhD
Peter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Advertisement
Peter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Learn more about the treatment of squamous cell lung cancer > >
Articles in this issue
almost 12 years ago
Veliparib Shows Potential in Squamous Cell NSCLCalmost 12 years ago
IDO Inhibitors May Augment Immunotherapy in NSCLCalmost 12 years ago
Multidisciplinary Teams in NSCLC Important for Optimal Patient Carealmost 12 years ago
The Role of Chemotherapy in the Treatment of Lung Canceralmost 12 years ago
The Challenges of Treating Lung Canceralmost 12 years ago
Early Detection and Molecular Testing Evolving for NSCLCAdvertisement
Related to this article
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
The phase 2/3 AHEAD-MERIT trial will continue to evaluate patients with HPV-positive head and neck squamous cell carcinoma for its second primary end point of overall survival.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5